Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib as Adjuvant Therapy for High-Risk Recurrent HCC
NCT06581315Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of donafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: One year recurrence-free survival rate at 1 year. Started Aug 2024; status: recruiting.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06581315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06581315.